MaxCyte

@MaxCyte_info

MaxCyte specializes in enabling the discovery and development of innovative therapeutics.

Gaithersburg, MD
Vrijeme pridruživanja: veljača 2015.

Tweetovi

Blokirali ste korisnika/cu @MaxCyte_info

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @MaxCyte_info

  1. prije 49 minuta

    CEO & President Doug Doerfler will present at BIO CEO & Investor Conf Feb 10 on how MaxCyte is driving the development of next generation cell-based therapies through its ExPERT™ instrument family, as well as its proprietary CARMA platform: .

    Poništi
  2. prije 20 sati

    A fundamental discovery about how activity is regulated: via .

    Poništi
  3. 3. velj

    DNA "scissors" could cut out the 's causing gene in mice: via .

    Poništi
  4. 31. sij

    Scientists at boost tools to new heights in human stem cells using TREE (Transient Reporter for Editing Enrichment), which allows for more accurate single-DNA base editing: via .

    Poništi
  5. 31. sij
    Poništi
  6. 30. sij

    Some cancer cells refuse to die, even in the face of powerful immunotherapies. New research from sheds light on why: via .

    Poništi
  7. 29. sij

    Researchers at use stem cells, , and gene sequencing technology to create a new brain model: via .

    Poništi
  8. 28. sij

    is the most common hereditary muscular disease among children. German researchers have developed a that may provide permanent relief: via .

    Poništi
  9. 27. sij

    Today is the day! We will be presenting a poster titled, "Advancing Adoptive Cellular Therapies Using Non-viral-based Engineering" at the International Conference on Base Editing Enzymes & Applications starting at 4pm. Stop by to learn more!

    Poništi
  10. 24. sij

    MaxCyte is presenting "Advancing Adoptive Cellular Therapies Using Non-viral-based Engineering" at the International Conference on Base Editing Enzymes & Applications Jan 27. Stop in & learn about our clinically validated, electroporation technology.

    Poništi
  11. 23. sij

    New findings using have shown that the IL-4 and IL-13 proteins can protect the body against inflammation from autoimmune diseases: .

    Poništi
  12. 22. sij

    MaxCyte will be at the 1st International Conference on Base Editing – Enzymes and Applications conference next week presenting a poster titled, "Advancing Adoptive Cellular Therapies Using Non-viral-based Engineering."

    Poništi
  13. 22. sij

    In a joint study with and published in found nearly 50 existing non-cancer drugs kill some cell lines in the lab: via .

    https://www.dana-farber.org/newsroom/news-releases/2020/dozens-of-potential-anti-cancer-drugs-netted-in-massive-screening-study/
    Poništi
  14. 21. sij

    Scientists at show protection of eyesight in models of multiple sclerosis: via .

    Poništi
  15. 17. sij

    Learning to speak genome: to become fluent in life’s molecular language, take immersion programs in single-cell transcriptomics, technology, and synthetic biology: via .

    Poništi
  16. 16. sij

    The kill-switch for that could make safer: how anti-CRISPR proteins and other molecules could bolster biosecurity and improve medical treatments: via .

    Poništi
  17. 15. sij

    Researchers from and developed protein editorial assistants to clear the way for DNA editors, like , to access previously inaccessible genes of interest: via .

    Poništi
  18. 15. sij

    Start the year off right by learning about our ExPERT instrument family, the industry’s leading, clinically validated, electroporation technology for complex & scalable cellular engineering.

    Poništi
  19. 14. sij

    Researchers at have discovered that cells can survive anti-cancer by altering their cytoskeleton. The results point to a strong connection between metastasis and therapy resistance: via .

    Poništi
  20. 13. sij

    Quest to use against disease gains ground. As the first clinical-trial results trickle in, researchers look ahead to more sophisticated medical applications for : via .

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·